Skip to main content

Sue Siegel, Michael Christman

Premium
Sue Siegel, formerly president emeritus of Affymetrix, has been named a partner at the Silicon Valley venture-capital firm Mohr Davidow Ventures.
 
Affymetrix disclosed that Siegel had resigned as president emeritus last week (see BAN 3/27/2007).
 
MDV said that Siegel will help the company “invest in cross-discipline companies” involved in clinical and medical technological development.
 
Siegel became president of Affy in 1999 and a director in 2001. She became president emeritus in 2006 after resigning as president and director.
 

 
Michael Christman will become president and CEO of the Coriell Institute for Medical Research on June 1. Christman will supervise the scientific and management operations at Coriell, and will also lead “a new initiative to identify human genetic variation that contributes to diseases such as cancer, heart disease, and obesity,” the institute said in a statement.
 
Christman most recently served as professor and founding chair of the department of genetics and genomics for the Boston University School of Medicine. He has also served as associate professor in the department of microbiology at the University of Virginia and as assistant professor in the department of radiation oncology at the University of California, San Francisco.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.